Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NAT1
UPID:
PMGT2_HUMAN
Alternative names:
Extracellular O-linked N-acetylglucosamine transferase-like; Glycosyltransferase-like domain-containing protein 2
Alternative UPACC:
Q8NAT1; B3KWC3; Q96SY3
Background:
Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2, also known as Extracellular O-linked N-acetylglucosamine transferase-like and Glycosyltransferase-like domain-containing protein 2, plays a crucial role in the biosynthesis of phosphorylated O-mannosyl trisaccharide. This carbohydrate structure is essential for alpha-dystroglycan to bind laminin G-like domain-containing extracellular proteins with high affinity.
Therapeutic significance:
The protein is implicated in Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8 and Muscular dystrophy-dystroglycanopathy limb-girdle C8. These conditions highlight the protein's critical role in muscle and brain development, presenting a target for therapeutic intervention in these muscular dystrophies.